Definitions and statistical properties of master protocols for personalized medicine in oncology

ABSTRACT Within the field of cancer research, discovery of biomarkers and genetic mutations that are potentially predictive of treatment benefit is motivating a paradigm shift in how cancer clinical trials are conducted. In this review, we provide an overview of the class of trials known as “master protocols,” including basket trials, umbrella trials, and platform trials. For each, we describe standardized terminology, provide a motivating example with modeling details and decision rules, and discuss statistical advantages and limitations. We conclude with a discussion of general statistical considerations and challenges encountered across these types of trials.

[1]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[2]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Brian P Hobbs,et al.  Controlled multi-arm platform design using predictive probability , 2018, Statistical methods in medical research.

[4]  M. Parmar,et al.  Evaluating many treatments and biomarkers in oncology: a new design. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Jänne,et al.  ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[6]  R. Mannel,et al.  Is the NCI MATCH trial a match for gynecologic oncology? , 2016, Gynecologic oncology.

[7]  A. Redig,et al.  Basket trials and the evolution of clinical trial design in an era of genomic medicine. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J M Reichert,et al.  Clinical Approval Success Rates for Investigational Cancer Drugs , 2013, Clinical pharmacology and therapeutics.

[9]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[10]  S. Mandrekar,et al.  Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. , 2015, Chinese clinical oncology.

[11]  Asher Mullard,et al.  NCI-MATCH trial pushes cancer umbrella trial paradigm , 2015, Nature Reviews Drug Discovery.

[12]  Mary W Redman,et al.  Lung-MAP--framework, overview, and design principles. , 2015, Chinese clinical oncology.

[13]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[14]  Boris Freidlin,et al.  Adaptive randomization versus interim monitoring. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[16]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[17]  R. Govindan,et al.  ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer , 2015, Clinical pharmacology and therapeutics.

[18]  Françoise Meunier,et al.  How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? , 2013, European journal of cancer.

[19]  Giovanni Parmigiani,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[20]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[21]  L. Billingham,et al.  Research methods to change clinical practice for patients with rare cancers. , 2016, The Lancet. Oncology.

[22]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[23]  S. Galbraith,et al.  The changing world of oncology drug development-A global pharmaceutical company's perspective. , 2014, Chinese clinical oncology.

[24]  Mary W Redman,et al.  The Master Protocol Concept. , 2015, Seminars in oncology.

[25]  Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. , 2015, The New England journal of medicine.

[26]  Edward S. Kim,et al.  Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.

[27]  B. Freidlin,et al.  Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[29]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[30]  Michael Hogarth,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[31]  Sumithra J Mandrekar,et al.  Precision oncology: A new era of cancer clinical trials. , 2017, Cancer letters.

[32]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[33]  James H. Doroshow,et al.  Phase III Clinical Trial Development: A Process of Chutes and Ladders , 2010, Clinical Cancer Research.

[34]  B. Besse,et al.  New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response , 2014, European Respiratory Review.

[35]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[36]  Richard Kaplan.  The FOCUS4 design for biomarker stratified trials. , 2015, Chinese clinical oncology.

[37]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[38]  Donald A Berry,et al.  The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research , 2015, Molecular oncology.

[39]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[40]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[41]  J. Lee,et al.  An overview of the design and conduct of the BATTLE trials. , 2015, Chinese clinical oncology.

[42]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[43]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[44]  Daniel V.T. Catenacci,et al.  Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.